Literature DB >> 21194775

Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes.

P M Bell1, J Cuthbertson, S Patterson, F P M O'Harte.   

Abstract

We examined the postprandial glucose regulators nateglinide and GLP-1, separately and in combination, in people with type 2 diabetes. Nateglinide inhibited DPP-4 activity, reduced GLP-1 degradation and enhanced its insulinotropic and blood glucose lowering effect. Combining nateglinide and GLP-1 derivatives may effectively control postprandial glycaemia.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21194775     DOI： 10.1016/j.diabres.2010.11.033

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  5 in total

1.  Efficacy and safety of nateglinide plus sitagliptin combination therapy in type 2 diabetes patients inadequately controlled by sitagliptin monotherapy: a phase 3, multicenter, open-label, long-term study.

Authors:  Takahisa Hirose; Chihiro Saitoh; Ichiro Oikawa; Nobuo Kondo
Journal:  Diabetol Int       Date:  2018-01-12

2.  Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide.

Authors:  Kyoko Kudo-Fujimaki; Takahisa Hirose; Tomoaki Yoshihara; Fumihiko Sato; Yuki Someya; Chie Ohmura; Akio Kanazawa; Yoshio Fujitani; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2013-11-05       Impact factor: 4.232

3.  Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study.

Authors:  Masumi Tanimoto; Akio Kanazawa; Takahisa Hirose; Tomoaki Yoshihara; Saeko Kobayashi-Kimura; Risa Nakanishi; Yuka Tosaka; Ruri Sasaki-Omote; Kyoko Kudo-Fujimaki; Koji Komiya; Fuki Ikeda; Yuki Someya; Tomoya Mita; Yoshio Fujitani; Hirotaka Watada
Journal:  J Diabetes Investig       Date:  2015-03-15       Impact factor: 4.232

4.  The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus.

Authors:  Rodolfo Guardado-Mendoza; Annamaria Prioletta; Lilia M Jiménez-Ceja; Aravind Sosale; Franco Folli
Journal:  Arch Med Sci       Date:  2013-04-30       Impact factor: 3.318

Review 5.  Modulatory Mechanisms of the NLRP3 Inflammasomes in Diabetes.

Authors:  Sujuan Ding; Sheng Xu; Yong Ma; Gang Liu; Hongmei Jang; Jun Fang
Journal:  Biomolecules       Date:  2019-12-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.